DT
HealthMore in Health→
Experimental Parkinson’s drug posts early signal by lowering linked protein in first human trial
An experimental gene-silencing drug reduced a Parkinson’s-linked protein by as much as 60% in an early human study, offering a measurable biological signal while leaving larger questions about clinical benefit for later,
Key Takeaways
- First-in-human trial reported encouraging effects.
- Experimental drug is designed to silence a gene strongly linked to Parkinson’s disease.
DE
DT Editorial Team··via medicalxpress.com